Anticoagulation management in the perioperative phase of implantable cardioverter defbrillator implantation

Circulation Journal

Volumn 77, Issue 8, 2013, Pages 2003-2008

  Yokoshiki, Hisashi ^a   Mitsuyama, Hirofumi ^a   Watanabe, Masaya ^a   Mizukami, Kazuya ^a   Matsui, Yoshiro ^a   Tsutsui, Hiroyuki ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anticoagulation; Bleeding complication; Heparin bridging; Implantable cardioverter defibrillator implantation

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; HEPARIN; THIENOPYRIDINE DERIVATIVE; WARFARIN;

ADULT; ARTICLE; BLEEDING; FEMALE; HEART TAMPONADE; HEMATOMA; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERICARDIAL EFFUSION; PERIOPERATIVE PERIOD; REOPERATION; RETROSPECTIVE STUDY;

AGED; ANTICOAGULANTS; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; WARFARIN;

EID: 84880776074     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1507     Document Type: Article

References (37)

1. A comparison of antiarrhythmic-drug therapy with implantable de-fbrillators in patients resuscitated from near-fatal ventricular arrhythmias: The Antiarrhythmics versus Implantable Defbrillators (AVID) Investigators. N Engl J Med 1997; 337: 1576-1583.
2. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al; Multicenter Automatic Defbrillator Implantation Trial II Investigators. Prophylactic implantation of a defbrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
3. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defbrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
4. Freeman JV, Wang Y, Curtis JP, Heidenreich PA, Hlatky MA. The relation between hospital procedure volume and complications of cardioverter-defbrillator implantation from the implantable cardio-verter-defbrillator registry. J Am Coll Cardiol 2010; 56: 1133-1139.
5. van Rees JB, Borleffs CJ, de Bie MK, Stijnen T, van Erven L, Bax JJ, et al. Inappropriate implantable cardioverter-defbrillator shocks: Incidence, predictors, and impact on mortality. J Am Coll Cardiol 2011; 57: 556-562.
6. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al. Prognostic importance of defbrillator shocks in patients with heart failure. N Engl J Med 2008; 359: 1009-1017.
7. Daubert JP, Zareba W, Cannom DS, McNitt S, Rosero SZ, Wang P, et al; MADIT II Investigators. Inappropriate implantable cardiovert-er-defbrillator shocks in MADIT II: Frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008; 51: 1357-1365.
8. Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N, et al; PEOPLE Study Group. Risk factors related to infections of implanted pacemakers and cardioverter-defbrillators: Results of a large prospective study. Circulation 2007; 116: 1349-1355.
9. JCS Joint Working Group. Guidelines for management of anticoagu-lation and antiplatelet therapy in cardiovascular disease (JCS 2009). http://www.j-circ.or.jp/guideline/ (accessed February 25, 2013).
10. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, et al. American College of Chest Physicians. The peri-operative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 299S-339S.
11. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, effcacy, and safety. Chest 2001; 119(1 Suppl): 64S-94S.
12. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists/clinical perspective: Systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012; 126: 1630-1639.
13. Michaud GF, Pelosi F Jr, Noble MD, Knight BP, Morady F, Strickberger SA. A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defbrillator implantation. J Am Coll Cardiol 2000; 35: 1915-1918.
14. Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE, et al. Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or im-plantable cardioverter-defbrillator device implantation. J Am Coll Cardiol 2010; 55: 2376-2382.
15. Ahmed I, Gertner E, Nelson WB, House CM, Dahiya R, Anderson CP, et al. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defbrillator implantation. Heart Rhythm 2010; 7: 745-749.
16. Kutinsky IB, Jarandilla R, Jewett M, Haines DE. Risk of hematoma complications after device implant in the clopidogrel era. Circ Ar-rhythm Electrophysiol 2010; 3: 312-318.
17. Ogawa S, Koretsune Y, Yasaka M, Aizawa Y, Atarashi H, Inoue H, et al. Antithrombotic therapy in atrial fbrillation: Evaluation and positioning of new oral anticoagulant agents. Circ J 2011; 75: 1539-1547.
18. Pisters R, Lane DA, Marin F, Camm AJ, Lip GYH. Stroke and throm-boembolism in atrial fbrillation: Systematic review of stroke risk factors and risk stratifcation schema. Circ J 2012; 76: 2289-2304.
19. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fbrillation. N Engl J Med 1996; 335: 540-546.
20. Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fbrillation: A multicenter, prospective, randomized trial: Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 2000; 31: 817-821.
21. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fbrillation. Intern Med 2001; 40: 1183-1188.
22. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-1511.
23. Carter CJ. The pathophysiology of venous thrombosis. Prog Cardio-vasc Dis 1994; 36: 439-446.
24. JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J 2011; 75: 1258-1281.
25. Yamada N, Nakamura M, Ito M. Current status and trends in the treatment of acute pulmonary thromboembolism. Circ J 2011; 75: 2731-2738.
26. Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008; 168: 63-69.
27. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fbrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57: e101-e198.
28. Wiegand UK, LeJeune D, Boguschewski F, Bonnemeier H, Eberhardt F, Schunkert H, et al. Pocket hematoma after pacemaker or implant-able cardioverter defbrillator surgery: Infuence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest 2004; 126: 1177-1186.
29. Robinson M, Healey JS, Eikelboom J, Schulman S, Morillo CA, Nair GM, et al. Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defbrillators. Pacing Clin Electro-physiol 2009; 32: 378-382.
30. Cheng M, Hua W, Chen K, Pu J, Ren X, Zhao X, et al. Perioperative anticoagulation for patients with mechanic heart valve(s) undertaking pacemaker implantation. Europace 2009; 11: 1183-1187.
31. Tolosana JM, Berne P, Mont L, Heras M, Berruezo A, Monteagudo J, et al. Preparation for pacemaker or implantable cardiac defbrilla-tor implants in patients with high risk of thrombo-embolic events: Oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. Eur Heart J 2009; 30: 1880-1884.
32. Li HK, Chen FC, Rea RF, Asirvatham SJ, Powell BD, Friedman PA, et al. No increased bleeding events with continuation of oral antico-agulation therapy for patients undergoing cardiac device procedure. Pacing Clin Electrophysiol 2011; 34: 868-874.
33. Goldstein DJ, Losquadro W, Spotnitz HM. Outpatient pacemaker procedures in orally anticoagulated patients. Pacing Clin Electro-physiol 1998; 21: 1730-1734.
34. Al-Khadra AS. Implantation of pacemakers and implantable cardio-verter defbrillators in orally anticoagulated patients. Pacing Clin Elec-trophysiol 2003; 26: 511-514.
35. Giudici MC, Paul DL, Bontu P, Barold SS. Pacemaker and implant-able cardioverter defbrillator implantation without reversal of warfarin therapy. Pacing Clin Electrophysiol 2004; 27: 358-360.
36. Cheng A, Nazarian S, Brinker JA, Tompkins C, Spragg DD, Leng CT, et al. Continuation of warfarin during pacemaker or implantable cardioverter-defbrillator implantation: A randomized clinical trial. Heart Rhythm 2011; 8: 536-540.
37. Birnie D, Healey JS, Krahn A, Essebag V, Sivakumaran S, Tang A, et al. Bridge or continue Coumadin for device surgery: A randomized controlled trial rationale and design. Curr Opin Cardiol 2008; 24: 82-87.